The potential for modified CYP11B2 gene expression to cause significant blood pressure effects is most starkly illustrated by the rare monogenic condition, glucocorticoid-remediable aldosteronism (GRA), where unequal crossing-over of this locus with that of the CYP11B1 gene (see below), leads to vastly increased expression of aldosterone synthase, elevating levels of aldosterone and resulting in severe hypertension [6]. This evidence concerns the gene CYP11B1 and hypertensive disorder.